Brief: Galera Announces Receipt Of Type A Meeting Minutes And Strategic Update

Galera Therapeutics

31/10/2023 11:17

Oct 31 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA ANNOUNCES RECEIPT OF TYPE A MEETING MINUTES AND
STRATEGIC
UPDATE
    * GALERA THERAPEUTICS INC - REVIEWING POTENTIAL STRATEGIC
ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE
    * GALERA THERAPEUTICS INC - FDA CONFIRMS NEED FOR NEW TRIAL
FOR
AVASOPASEM FOR SEVERE ORAL MUCOSITIS (SOM)
    * GALERA THERAPEUTICS INC - GRECO-2 TRIAL DID NOT PASS
FUTILITY
ANALYSIS; COMPANY WILL DISCONTINUE BOTH GRECO TRIALS
    * GALERA THERAPEUTICS INC - DECIDED TO HALT PHASE 2B GRECO-2
TRIAL
OF RUCOSOPASEM MANGANESE (RUCOSOPASEM) IN PATIENTS WITH LOCALLY
ADVANCED PANCREATIC CANCER
    * GALERA THERAPEUTICS INC - DECIDED TO HALT PHASE 1/2
GRECO-1
TRIAL OF RUCOSOPASEM IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    * GALERA THERAPEUTICS INC - ESTIMATES THAT ITS BALANCE OF
CASH,
CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30,
2023 WAS $28.4 MILLION

Source text for Eikon:  ID:nGNX32ygV0 
Further company coverage:  GRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))